This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

EU Pharmaceutical Law Forum

£300 SAVINGS END IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
EU Pharmaceutical Law Forum 2024
May 21-23, 2024Steigenberger Wiltcher's, Brussels
EU Pharmaceutical Law Forum 2024
May 21-23, 2024,
Steigenberger Wiltcher's, Brussels

Join White & Case at EU Pharmaceutical Law Forum 2024

You're Invited to EU Pharma Law with an Exclusive 10% Off

We are excited to announce that White & Case will be participating at the EU Pharmaceutical Law Forum on 21-23 May 2024 at the Steigenberger Wiltcher's Hotel, Brussels. And, we are pleased to let you know that as a valued client of White & Case, we have an exclusive 10% discount* for you. Your VIP discount code is: P24WHITECASE

*T&C's Apply

Regulatory Scrutiny on Deals: Update on Foreign Direct Investment Screening

  • Growth of protectionist policies internationally and their impact for pharmaceutical commercial transactions and collaborations

  • Avoiding delays: knowledge on national requirements for the disclosure of knowledge and of supply chain management issues

TRI DIALOGUE Key Developments at the Intersection of Antitrust and Intellectual Property

  • Implications of the Teva/Copaxone case and Novartis case on unilateral conduct and divisional strategies for IP and reg exclusivities

  • Potential implications if the EU Commission adopt a new theory of harm

  • Implications from the Servier case: where are we with patent settlements and practical guidance on managing antitrust risk

DUAL DIALOGUE Success Factors for Licensing Life Science Deals

  • Discussing the more challenging, yet common risks in license collaboration, true JVs, M&A and investment deals

  • Key market insight: what are killing commercial deals? Changing case law and emerging risks

  • Areas of risk: operational behavior preceding the deal and practical things that crop up during and after the deals